<DOC>
	<DOCNO>NCT00615212</DOCNO>
	<brief_summary>This study mean assess potential inhibitory effect GSK376501 CYP450 isoenzymes 3A4 , 2C8 , 2C9 . subject receive probe compound systemic level substrate compare pre post dose GSK376501 .</brief_summary>
	<brief_title>Effect GSK376501 CYP450 Activity Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy determine qualified physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator considers find unlikely introduce additional risk factor interfere study procedure . Male female 18 55 year age . A female subject eligible participate nonchildbearing potential , define : a. premenopausal female document tubal ligation hysterectomy ; b. postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Body weight ≥ 50 kg BMI within range 19 30 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Demonstrates average QTc interval &lt; 450 msec ( &lt; 480 msec subject bundle branch block ) , average PR interval &lt; 200 msec , QRS duration &lt; 110msec ( manual machine read ) screen baseline A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Previous exposure GSK376501 . Unwillingness inability follow procedure outline protocol . Demonstrates symptomatic asymptomatic arrhythmia clinical significance screening . The subject positive prestudy drug/alcohol screen unwilling abstain 72 hour prior dose followup . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Urinary cotinine level indicative smoke history use tobacco nicotinecontaining product within 6 month prior screen . Has history alcohol abuse dependence within 12 month prior study . Alcohol abuse define average consumption great 7 drink per week woman great 14 drink per week men . One alcohol drink define equivalent 12 g alcohol follow : 5 oz/150 ml wine , 12 oz ( 360 ml ) beer 1.5 oz ( 45 ml ) 80 proof distil spirit . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort , kava , ephedra [ huang ] , gingko biloba , DHEA , vohimbe , saw palmetto , ginseng , red yeast rice ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication unwilling abstain use medication last pharmacokinetic pharmacodynamic sample collect , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Use caffeine xanthinecontaining product 24 hour prior dose last pharmacokinetic sample collect . Consumption food beverage containing ( alcohol , grapefruit grapefruit juice , apple orange juice , Seville oranges , vegetable mustard green family [ e.g. , kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ] charbroiled meat ) . 7 day prior first dose study medication . Use acetaminophen within 48 hour first dose unable unwilling discontinue use acetaminophen last pharmacokinetic sample collect . Use aspirin , aspirincontaining compound , salicylate nonsteroidal antiinflammatory drug ( NSAIDs ) within 48 hour day first dose unwilling abstain use medication last pharmacokinetic sample collect . Use liquid antacid ( e.g . Maalox , Mylanta , Amphogel , milk magnesia ) chewable antacid ( e.g . TUMS™ ) within 48 hour first dose unwilling abstain use medication last dose study medication . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Alkaline phosphatase value high 1.5 time upper limit normal screen baseline . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , direct ( conjugate ) bilirubin , CPK value high 1.25 time upper limit normal screen baseline . Fasting triglyceride level &gt; 400 mg/dL ( 4.52 mmol/L ) screen baseline . Triglyceride level within 10 % margin level consider casebycase basis . Donation blood blood product excess 500 mL within 56 day period . History sensitivity heparin heparininduced thrombocytopenia . History current congestive heart failure ( NYHA Class IIV symptom ) History thyroid dysfunction abnormal thyroid function test assess TSH screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>GSK376501 ,</keyword>
	<keyword>Cytochrome P450 isoenzymes ,</keyword>
	<keyword>Healthy Subjects ,</keyword>
	<keyword>Repeat Dose</keyword>
</DOC>